Realta Life Sciences raised an additional $40 million in the final tranche of its Series A, bringing total funding to more than $150 million as the company advances its treatment for hypoxic ischemic encephalopathy (HIE). The financing was structured through mission-driven investors and a family-office model. The raise positions Realta to sustain development in a neonatal indication where therapeutic windows and clinical trial design are key to differentiating candidates. HIE remains a high-stakes area because outcomes can vary widely without timely intervention. For biotech capital allocation, the added tranche highlights investor willingness to underwrite early clinical programs with clear clinical urgency and institutional support, even as many therapeutic areas compete for limited risk capital. The funding should help Realta preserve operational momentum and support later-stage readiness as the asset moves through development milestones.